Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

pharmiweb.com today archive

2152 PWToday Stories

Eisai enrolls patients in global phase III trial to evaluate first-line Kisplyx® (lenvatinib) plus pembrolizumab or everolimus versus sunitinib in advanced renal cell carcinoma

04 Oct 16

Eisai today announces the initiation of a multicentre, global, randomised phase III study that will evaluate the efficacy and safety of lenvatinib in combination with
anti-PD-1 immunotherapy pembrolizumab and lenvatinib in combination with everolimus versus sunitinib in patients with advanced renal cell carcinoma (RCC) in a first-line setting. Pembrolizumab is marketed under the brand name Keytruda® by Merck, Sharp & Dohme (MSD) in the European Union.

 

Study 307 (ClinicalTrials.gov identifier: NCT02811861) (Comparison of the efficacy and safety of Lenvatinib in combination with Everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with Advanced Renal cell carcinoma) is designed to assess the progression-free survival (PFS) of patients treated with these combinations.1 Secondary endpoints include objective response rate, overall survival and safety. Study 307 is the first phase III trial to assess lenvatinib in combination with pembrolizumab, an anti-PD-1 (programmed death receptor-1) immunotherapy, in previously untreated patients with advanced RCC.1,[ii]

 

Kidney cancer is among the ten most frequently occurring cancers in Western (countries) communities.3 About 270,000 cases of kidney cancer are diagnosed globally each year and 116,000 people die from the disease.3 Approximately 90% of all kidney cancers are renal cell carcinomas (RCC).[iii]

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.